MIST

Milestone Pharmaceuticals Inc

MIST, USA

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

https://www.milestonepharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MIST
stock
MIST

Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST) Seeking Alpha

Read more →
MIST
stock
MIST

MIST Stock Upgraded to 'Buy' by TD Cowen with New Price Target | GuruFocus

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$3.75

Analyst Picks

Strong Buy

0

Buy

2

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

7.80

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-58.15 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-13.59 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

3.28

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 16.90% of the total shares of Milestone Pharmaceuticals Inc

1.

Simplify Propel Opportunities ETF

(3.3331%)

since

2025/07/31

2.

RTW INVESTMENTS, LLC

(2.9486%)

since

2025/06/30

3.

Propel Bio Management LLC

(2.1079%)

since

2025/06/30

4.

Alta Fundamental Advisers LLC

(1.646%)

since

2025/06/30

5.

BML Capital Management LLC

(1.3367%)

since

2025/06/30

6.

Simplify Asset Management Inc.

(1.1648%)

since

2025/06/30

7.

Morgan Stanley - Brokerage Accounts

(0.9653%)

since

2025/06/30

8.

The Toronto-Dominion Bank

(0.8824%)

since

2025/06/30

9.

Lion Point Capital, LP

(0.6457%)

since

2025/06/30

10.

Bleichroeder LP

(0.5883%)

since

2025/06/30

11.

UBS Group AG

(0.3796%)

since

2025/06/30

12.

XTX Topco Ltd

(0.1894%)

since

2025/06/30

13.

Valeo Financial Advisors, LLC

(0.1538%)

since

2025/06/30

14.

Goldman Sachs Group Inc

(0.1405%)

since

2025/06/30

15.

Cascades Capital Asset Management, LLC

(0.079%)

since

2025/06/30

16.

Susquehanna International Group, LLP

(0.0746%)

since

2025/06/30

17.

Northern Trust Corp

(0.0624%)

since

2025/06/30

18.

The Colony Group LLC

(0.0424%)

since

2025/06/30

19.

Royal Bank of Canada

(0.0419%)

since

2025/06/30

20.

Jane Street Group LLC

(0.0376%)

since

2025/06/30

21.

Group One Trading, LP

(0.0372%)

since

2025/06/30

23.

Fidelity Nasdaq Composite Index

(0.0211%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.178

Latest Release

Date

2025-09-30

EPS Actual

-0.12

EPS Estimate

-0.16

EPS Difference

0.04

Surprise Percent

25%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.